Astrazeneca (AZN) Non Operating Income (2016 - 2026)

Astrazeneca has reported Non Operating Income over the past 16 years, most recently at $320.0 million for Q1 2026.

For Q1 2026, Non Operating Income rose 220.75% year-over-year to $320.0 million; the TTM value through Mar 2026 reached $1.9 billion, up 1035.5%, while the annual FY2025 figure was $1.3 billion, 3.89% up from the prior year.
Non Operating Income for Q1 2026 was $320.0 million at Astrazeneca, down from $349.0 million in the prior quarter.
Over five years, Non Operating Income peaked at $901.0 million in Q2 2025 and troughed at -$945.0 million in Q4 2023.
A 5-year average of $161.3 million and a median of $319.0 million in 2022 define the central range for Non Operating Income.
On a YoY basis, Non Operating Income climbed as much as 227.37% in 2025 and fell as far as 187.75% in 2025.
Year by year, Non Operating Income stood at $293.0 million in 2022, then crashed by 422.53% to -$945.0 million in 2023, then surged by 138.62% to $365.0 million in 2024, then fell by 4.38% to $349.0 million in 2025, then decreased by 8.31% to $320.0 million in 2026.
Business Quant data shows Non Operating Income for AZN at $320.0 million in Q1 2026, $349.0 million in Q4 2025, and $349.0 million in Q3 2025.

Peer Comparison